Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

Found 1417 recommendations for 667 medicines and 153 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
  1. BCG vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Ebola vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Japanese encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  4. Medicines for COVID-19 General information
    Section
    Medicines for COVID-19
    • Refer to WHO living guidelines
    Indications
    COVID-19
  5. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  6. Abacavir + dolutegravir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  7. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  8. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  9. Acamprosate calcium General information
    Section
    Medicines for alcohol use disorders
    • Oral > Solid > tablet: 333 mg
    Indications
    Disorders due to use of alcohol
  10. Acenocoumarol General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to warfarin for Other specified diseases of arteries or arterioles Therapeutic equivalent to warfarin for Venous thromboembolism Therapeutic equivalent to warfarin for Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin for Atrial fibrillation
  11. Acetazolamide General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
    Indications
    Primary open-angle glaucoma
  12. Acetic acid General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% solution
    Indications
    Infectious diseases of external ear
  13. Acetylcysteine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  14. Acetylsalicylic acid General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Indications
    Acute myocardial infarction Cerebral ischaemic stroke
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Pain
    Section
    Medicines for acute migraine attacks
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Medicines for juvenile joint diseases
    • Local > Rectal > Suppository: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg
    • Oral > Solid > tablet: 75 to 500 mg
    Indications
    Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis
  15. Acetylsalicylic acid + atorvastatin + ramipril General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  16. Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
    Indications
    Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke
  17. Aciclovir General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
    Indications
    Herpes simplex keratitis
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    Indications
    Herpes simplex infections Zoster Varicella
    Section
    Medicines for viral central nervous system infections
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    • Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)
    Indications
    Herpes simplex infections Zoster Varicella
  18. Aclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  19. Activated charcoal General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 50 mg granules for oral suspension
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  20. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.
    Indications
    Psoriasis of unspecified type
  21. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  22. Albendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Echinococcosis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis Ascariasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
    Indications
    Other specified echinococcosis Cysticercosis of central nervous system
    Section
    Antifilarials
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Lymphatic filariasis
  23. Alcohol based hand rub General information
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
    Indications
    Denatured alcohol
  24. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  25. Allopurinol General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Gout
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  26. Alprostadil (prostaglandin E1) General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
    Indications
    Other specified congenital anomaly of great arteries including arterial duct
  27. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  28. Amidotrizoate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
    Amidotrizoate
  29. Amikacin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)
    Second choice
    co-prescribed with cloxacillin Sepsis without septic shock
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  30. Amiloride General information
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
    Indications
    Oedema Ascites
  31. Amiodarone General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  32. Amitriptyline General information
    Section
    Medicines for depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Indications
    Depressive disorders
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 25 mg per 5 mL
    • Oral > Solid > tablet: 25 mg; 10 mg; 75 mg
    Indications
    Palliative care
  33. Amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
    Indications
    Essential hypertension
  34. Amodiaquine - sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package
    Indications
    Malaria
  35. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Periapical abscess without sinus Acute otitis media Acute sinusitis co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
    Section
    Medicines for bacterial central nervous system infections
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    Indications
    Second choice
    Bacterial meningitis
  36. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    First choice
    Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Osteomyelitis or osteitis Acute otitis media Other specified prophylactic measures Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  37. Amphotericin B General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Blastomycosis Cryptococcosis Candidosis Coccidioidomycosis Histoplasmosis Sporotrichosis Aspergillosis
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Indications
    Visceral leishmaniasis
  38. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritonitis (severe) co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Bacterial meningitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Bacterial meningitis
  39. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  40. Anidulafungin General information
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin for Systemic or invasive candidosis
  41. Ansuvimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  42. Anti-D immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Rh incompatibility reaction Maternal care for red cell antibodies
  43. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  44. Anti-rabies virus monoclonal antibodies General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  45. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  46. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  47. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  48. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid > capsule: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  49. Aripiprazole General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone for Schizophrenia or other primary psychotic disorders
  50. Arpraziquantel General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Therapeutic equivalent to praziquantel for Schistosomiasis
  51. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  52. Artemether General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  53. Artemether + lumefantrine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > dispersible tablet: 20 mg + 120 mg
    • Oral > Solid > tablet: 20 mg + 120 mg
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  54. Artesunate General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
    • Local > Rectal > Other: 100 mg capsules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  55. Artesunate + amodiaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
    • Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  56. Artesunate + mefloquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  57. Artesunate + pyronaridine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)
    • Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  58. Artesunate - sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  59. Ascorbic acid General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Scurvy
  60. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  61. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  62. Atenolol General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  63. Atezolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung
  64. Atoltivimab + maftivimab + odesivimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  65. Atorvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  66. Atorvastatin + perindopril + amlodipine General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
    Indications
    Chronic ischaemic heart disease Atherosclerotic chronic arterial occlusive disease Cerebral ischaemic stroke
  67. Atracurium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
    Muscle relaxants Therapeutic equivalent to vecuronium for Muscle relaxants
  68. Atropine General information
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Anterior uveitis
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)
    Indications
    Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
  69. Azathioprine General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 25 mg; 50 mg (scored)
    Indications
    Failure or rejection of transplanted organs or tissues
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 50 mg (scored)
    Indications
    Rheumatoid arthritis, serology unspecified Psoriatic arthritis
  70. Azithromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Trachoma
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    Chlamydia trachomatis Typhoid fever Yaws Paratyphoid fever Cholera Cholera [children] Trachoma co-prescribed with ceftriaxone Gonococcal infection
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection
  71. Baclofen General information
    Section
    Medicines for cerebral palsy
    • Oral > Liquid: 10 mg per 5 mL
    • Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule
    • Oral > Solid > tablet: 10 mg
    Indications
    Spastic cerebral palsy
  72. Barium sulfate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
    Barium sulfate with suspending agents
  73. Beclometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  74. Beclometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  75. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  76. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  77. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
    Indications
    First choice
    Syphilis Congenital syphilis [children]
  78. Benznidazole General information
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
    Indications
    Chagas disease
  79. Benzoyl peroxide General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
    Acne
  80. Benzyl benzoate General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
    Indications
    Pthiriasis Pediculosis corporis Pediculosis capitis Scabies
  81. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    First choice
    Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Bacterial meningitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    Second choice
    Bacterial meningitis
  82. Beractant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  83. Betamethasone General information
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
    Indications
    Pruritus due to skin disorder Psoriasis of unspecified type Dermatitis or eczema Lichen planus
  84. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
  85. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  86. Biperiden General information
    Section
    Medicines for parkinsonism
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
    Indications
    Parkinson disease
  87. Bisacodyl General information
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna for Constipation
  88. Bisoprolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Angina pectoris
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Heart failure
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Essential hypertension
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Cardiac arrhythmia
  89. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
    Indications
    Germ cell tumour of testis Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary
  90. Blinatumomab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
    Indications
    B lymphoblastic leukaemia or lymphoma, not elsewhere classified
  91. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  92. Bromocriptine General information
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands
  93. Budesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler
    • Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler
    Indications
    Asthma
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation
    Indications
    Allergic rhinitis
  94. Budesonide + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler
    Indications
    Asthma
  95. Budesonide + salmeterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  96. Bumetanide General information
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
  97. Bupivacaine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution
    • Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  98. Buprenorphine General information
    Section
    Medicines for opioid use disorders
    Indications
    Therapeutic equivalent to methadone for Opioid dependence
  99. Bupropion General information
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
    Indications
    Nicotine dependence
  100. Cabergoline General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
  101. Caffeine citrate General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    Indications
    Apnoea of newborn
  102. Calamine General information
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
    Pruritus
  103. Calcipotriol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
    Indications
    Psoriasis of unspecified type
  104. Calcitriol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type
  105. Calcium General information
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
    Indications
    Calcium deficiency
  106. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon Burkitt lymphoma including Burkitt leukaemia Malignant neoplasm metastasis in large intestine
  107. Calcium gluconate General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Tetany due to acute calcium deficiency
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)
    Indications
    Hypermagnesaemia
  108. Canagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  110. Carbachol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
    Therapeutic equivalent to pilocarpine for Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine for Ocular hypertension Therapeutic equivalent to pilocarpine for Primary open-angle glaucoma
  111. Carbamazepine General information
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
    Indications
    Bipolar or related disorders
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    Indications
    Epilepsy or seizures
  112. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  113. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  114. Carboplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Other specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Malignant neoplasms of cervix uteri
  115. Carvedilol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
  116. Caspofungin General information
    Section
    Antifungal medicines
    Indications
    Therapeutic equivalent to micafungin for Systemic or invasive candidosis
  117. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    First choice
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation
  118. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
  119. Cefiderocol General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  120. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection
  121. Cefotaxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate)
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis
  122. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    co-prescribed with vancomycin Endophthalmitis
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic
  123. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  124. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  125. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with vancomycin Endophthalmitis
    Second choice
    Bacterial infection of joint Osteomyelitis or osteitis Infectious gastroenteritis or colitis without specification of infectious agent Sepsis without septic shock Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate)
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis
  126. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  127. Cemiplimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung
  128. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
  129. Cetirizine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type
  130. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  131. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choice
    Bacterial meningitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choice
    Bacterial meningitis
  132. Chlorhexidine General information
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Indications
    Omphalitis of newborn
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
    Chlorhexidine
  133. Chlorine base compound General information
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
    Indications
    Disinfectant, not elsewhere classified
  134. Chloroquine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
    Indications
    Rheumatoid arthritis
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Liquid: 50 mg per 5 mL (base)
    • Oral > Solid > tablet: 150 mg (base)
    Indications
    Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Liquid: 50 mg per 5 mL (base)
    • Oral > Solid > tablet: 150 mg (base)
    Indications
    Malaria due to Plasmodium vivax
  135. Chlorothiazide General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  136. Chloroxylenol General information
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
    Indications
    Phenol disinfectant, not elsewhere classified
  137. Chlorpromazine General information
    Section
    Medicines for psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride)
    Indications
    Therapeutic equivalent to haloperidol for Schizophrenia or other primary psychotic disorders
  138. Chlortalidone General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  139. Chlortetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma
  140. Cholera vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  141. Ciclesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  142. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  143. Ciprofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Indications
    Infectious diseases of external ear
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Indications
    First choice
    Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Acute pyelonephritis (mild to moderate)
    Second choice
    Cholera Cholera [children] co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate)
  145. Cladribine General information
    Section
    Medicines for multiple sclerosis
    • Oral > Solid > tablet: 10 mg
    Indications
    Multiple sclerosis
  146. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid > dosage form: 500 mg
    Indications
    First choice
    co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choice
    Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Other indications
    Helicobacter pylori associated gastric ulcer
  147. Clindamycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    First choice
    co-prescribed with piperacillin + tazobactam Necrotising fasciitis
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
  148. Clofazimine General information
    Section
    Antileprosy medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Leprosy
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  149. Clomifene General information
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
    Indications
    Female infertility without specification whether primary or secondary
  150. Clomipramine General information
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Obsessive-compulsive disorder
  151. Clopidogrel General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  152. Clotrimazole General information
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
    Indications
    Vulvovaginal candidosis
  153. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    First choice
    Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    co-prescribed with amikacin Sepsis without septic shock
  154. Clozapine General information
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  155. Coagulation factor IX complex General information
    Section
    Coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX, plasma-derived for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived for Haemophilia B
  156. Coagulation factor IX, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  157. Coagulation factor IX, recombinant General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection
    Indications
    Haemophilia B
  158. Coagulation factor VIII, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  159. Coagulation factor VIII, recombinant General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection
    Indications
    Haemophilia A
  160. Coal tar General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Psoriasis of unspecified type
  161. Codeine General information
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Pain
  162. Colecalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
    Indications
    Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Calcium deficiency
  163. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  164. Compound sodium lactate solution General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock
  166. Copper-containing intrauterine device General information
    Section
    Intrauterine devices
    • -
    Indications
    Contact with health services for insertion of contraceptive device
  167. Cryoprecipitate (not pathogen-reduced) General information
    Section
    Blood and blood components
    Indications
    Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Obstetric haemorrhage
  168. Cryoprecipitate (pathogen-reduced) General information
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage
  169. Cyclizine General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 50 mg per mL (lactate)
    • Oral > Solid > tablet: 50 mg (hydrochloride)
    Indications
    Palliative care
  170. Cyclopentolate General information
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine for Anterior uveitis
  171. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    Indications
    Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Rhabdomyosarcoma primary site Hodgkin lymphoma Plasma cell myeloma Other specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  172. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  174. Cytisine (cytisinicline) General information
    Section
    Medicines for nicotine use disorders
    • Oral > Solid > tablet: 1.5 mg
    Indications
    Nicotine dependence
  175. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  176. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  177. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)
    Indications
    Chronic hepatitis C
  178. Daclatasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg
    Indications
    Chronic hepatitis C
  180. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  181. Dapagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  182. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  183. Darbepoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  184. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  185. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  186. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Myeloid leukaemia
  187. Deferasirox General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine for Thalassaemias
  188. Deferiprone General information
    Section
    Other medicines for haemoglobinopathies
    Indications
    Therapeutic equivalent to deferasirox for Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox for Thalassaemias
  189. Deferoxamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  190. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 25 mg
    • Oral > Solid > tablet: 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  191. Dengue vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  192. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 150 µg per actuation (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  193. Dexamethasone General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Indications
    Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
    Section
    Hormones and antihormones
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base
    • Oral > Solid > tablet: 4 mg (as dexamethasone base)
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    Indications
    Anaplastic large cell lymphoma, ALK-negative Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-positive
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equialent to 3.3 mg dexamethasone base)
    • Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)
    Indications
    Palliative care
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
    • Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)
    Indications
    Nausea or vomiting
  194. Dextran 70 General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
    Hypovolaemia
  196. Diazepam General information
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Anxiety
    Section
    Antiseizure medicines
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    Indications
    Therapeutic equivalent to lorazepam for Status epilepticus Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    • Parenteral > General injections > unspecified: 5 mg per mL
    • Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)
    Indications
    Palliative care
  197. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  198. Diethylcarbamazine General information
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
    Indications
    Lymphatic filariasis
  199. Digoxin General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
    Indications
    Heart failure
  200. Dihydroartemisinin + piperaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
    • Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  201. Diloxanide General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
    Amoebiasis
  202. Dimercaprol General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  203. Dinoprostone (prostaglandin E2) General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
    Indications
    Therapeutic equivalent to alprostadil (prostaglandin E1) for Other specified congenital anomaly of great arteries including arterial duct
  204. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  205. Diphtheria vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  206. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate
  207. Docusate sodium General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL
    • Oral > Solid > capsule: 100 mg
    Indications
    Palliative care
  208. Dolasetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  209. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  210. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  211. Dopamine General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
    Indications
    Heart failure Cardiogenic shock
  212. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Malignant neoplasms of breast Hodgkin lymphoma Plasma cell myeloma Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified
  213. Doxorubicin (as pegylated liposomal) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  214. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dosage form: 100 mg (as hyclate)
    Indications
    First choice
    Chlamydia trachomatis Cholera
    Second choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Chronic obstructive pulmonary disease with acute exacerbation Cholera [children]
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    Indications
    Malaria due to Plasmodium falciparum
  215. Dulaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  216. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  217. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  218. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  219. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  220. Eflornithine General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
    Indications
    Gambiense trypanosomiasis
  221. Eletriptan General information
    Section
    Medicines for acute migraine attacks
    • Oral > Solid > tablet: 40 mg
    Indications
    Therapeutic equivalent to sumatriptan for Migraine
  222. Elexacaftor + tezacaftor + ivacaftor General information
    Section
    Medicines for cystic fibrosis
    • Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg
    • Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet
    Indications
    Cystic fibrosis
  223. Emicizumab General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  224. Empagliflozin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  225. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
  226. Enalapril General information
    Section
    Antihypertensive medicines
    • Oral > Liquid: 1 mg per mL (as hydrogen maleate)
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Heart failure
  227. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  228. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  229. Enzalutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate
  230. Ephedrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
    Cardiac complications of anaesthesia during labour or delivery
  231. Epinephrine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Cardiac arrest
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Indications
    Primary open-angle glaucoma
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Asthma Chronic obstructive pulmonary disease
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Anaphylaxis
  232. Epoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  233. Epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  234. Epoetin theta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  235. Equine rabies immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  236. Ergocalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
    Indications
    Therapeutic equivalent to colecalciferol for Calcium deficiency Therapeutic equivalent to colecalciferol for Vitamin D deficiency Vitamin D deficiency Calcium deficiency
  237. Ergometrine General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
    Indications
    Postpartum haemorrhage
  238. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  239. Erythromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Indications
    Chlamydial conjunctivitis Gonococcal infection of eye
    Section
    Watch group antibiotics
    Indications
    Second choice
    Therapeutic equivalent to clarithromycin for Acute pharyngitis
  240. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  241. Estradiol cypionate + medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
    Indications
    Contact with health services for reasons associated with reproduction
  242. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
  243. Ethambutol General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Tuberculosis
  244. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  245. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  246. Ethanol General information
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
    Indications
    Denatured alcohol
  247. Ethinylestradiol + etonogestrel General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
    Indications
    Contact with health services for contraceptive management
  248. Ethinylestradiol + levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 µg + 150 µg
    Indications
    Contact with health services for contraceptive management
  249. Ethinylestradiol + norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
    Indications
    Contact with health services for contraceptive management
  250. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 125 mg
    • Oral > Solid > tablet: 250 mg
    Indications
    Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis
  251. Ethosuximide General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
    Indications
    Absence seizures, typical
  252. Etonogestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
    Indications
    Contact with health services for insertion of contraceptive device
  253. Etoposide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Ewing sarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Burkitt lymphoma including Burkitt leukaemia
  254. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  255. Fentanyl General information
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
    Indications
    Chronic cancer pain
  256. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
    • Oral > Solid > tablet: 60 to 65 mg elemental iron
    Indications
    Iron deficiency anaemia
  257. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida
  258. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid > tablet: 600 mg
    • Oral > Solid: 600 mg
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 600 mg
    • Oral > Solid: 600 mg
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
  259. Fexofenadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type
  260. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  261. Fluconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
    • Oral > Solid > capsule: 50 mg
    Indications
    Cryptococcosis Candidosis
  262. Flucytosine General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
    Cryptococcosis
  263. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  264. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Liquid: 100 µg per mL
    • Oral > Solid > tablet: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  265. Flunisolide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  266. Fluorescein General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
    Fluorescein
  267. Fluoride General information
    Section
    Dental medicines and preparations
    • Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
    • Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
    • Local > Dental > Varnish: 22500 ppm fluoride (any type)
    Indications
    Dental caries
  268. Fluorouracil General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
    Plantar warts
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in vial
    Indications
    Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon
  269. Fluoxetine General information
    Section
    Medicines for depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Depressive disorders
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Palliative care
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Social anxiety disorder Generalised anxiety disorder Panic disorder
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Obsessive-compulsive disorder
  270. Fluphenazine General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
    Schizophrenia or other primary psychotic disorders
  271. Flutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  272. Fluticasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  273. Fluticasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  274. Fluticasone furoate + vilanterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  275. Fluvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  276. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 400 µg
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    Indications
    Anencephaly or similar anomalies Spina bifida Cephalocele Folate deficiency anaemia
  277. Fomepizole General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  278. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  279. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  280. Furosemide General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Anuria or oliguria Oedema
  281. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  282. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  283. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Sepsis without septic shock co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shock
    Second choice
    Other specified prophylactic measures Gonococcal infection
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
    Indications
    Other specified conjunctivitis Infectious blepharitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis
  284. Glass ionomer cement General information
    Section
    Dental medicines and preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
    Dental caries
  285. Glatiramer acetate General information
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
    Indications
    Multiple sclerosis
  286. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 20 mg granules
    • Oral > Solid > tablet: 100 mg + 40 mg
    Indications
    Chronic hepatitis C
  287. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  288. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent
    Indications
    Hypoglycaemia in the context of diabetes
  289. Glucose General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypoglycaemia without associated diabetes
  290. Glucose + sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  291. Glutaral General information
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
    Indications
    Glutaral nonmedicinal
  292. Glycerol General information
    Section
    Dermatological medicines > Moisturizers
    • Local > Topical > Cream: 15 to 20%
    Indications
    Atopic eczema
  293. Glyceryl trinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
    Angina pectoris
  294. Glycopyrronium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  295. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  296. Goserelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  297. Granisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  298. Griseofulvin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
    Dermatophytosis
  299. Haemophilus influenzae type b vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  300. Haloperidol General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Palliative care
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Solid: 2 mg; 5 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  301. Haloperidol decanoate General information
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders
  302. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  303. Hepatitis A vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  304. Hepatitis B vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  305. Hepatitis E vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  306. Homatropine General information
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine for Anterior uveitis
  307. Human papilloma virus (HPV) vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  308. Hydralazine General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Gestational hypertension
  309. Hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Solid > dosage form: 25 mg; 12.5 mg
    Indications
    Oedema
  310. Hydrocortisone General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Anaphylaxis
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Indications
    Crohn disease site Ulcerative colitis
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
    Indications
    Dermatitis or eczema Lichen planus Pruritus due to skin disorder Psoriasis of unspecified type
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
    • Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule
    Indications
    Adrenocortical insufficiency
  311. Hydromorphone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  312. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  313. Hydroxycarbamide (hydroxyurea) General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
    Section
    Cytotoxic medicines
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  314. Hydroxychloroquine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
    Indications
    Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type
  315. Hyoscine butylbromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
    Palliative care
  316. Hyoscine hydrobromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
    Palliative care
  317. Hypochlorous acid General information
    Section
    Disinfectants
    • Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million
    Indications
    Disinfectant, not elsewhere classified
  318. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  319. Ibuprofen General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Indications
    Patent arterial duct
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
    Indications
    Pain
    Section
    Medicines for acute migraine attacks
    • Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
    Migraine
  322. Imipenem + cilastatin General information
    Section
    Watch group antibiotics
    Indications
    Second choice
    Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
  323. Indapamide General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  324. Indometacin General information
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen for Patent arterial duct
  325. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to adalimumab for Psoriasis of unspecified type
  326. Influenza vaccine (seasonal) General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  327. Insulin (analogue, long-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  328. Insulin (analogue, rapid-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  329. Insulin (human, intermediate-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  330. Insulin (human, short-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  331. Insulin aspart General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  332. Insulin degludec General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  333. Insulin detemir General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  334. Insulin glargine General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  335. Insulin glulisine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  336. Insulin lispro General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  337. Intraperitoneal dialysis solution General information
    Section
    Peritoneal dialysis solution
    • Solution: of appropriate composition in accordance with local clinical guidelines.
    Indications
    Care involving peritoneal dialysis
  338. Iodine General information
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine for Povidone iodine
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)
    Indications
    Iodine deficiency
  339. Iodine + potassium iodide (Lugol's solution) General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 5% w/v + 10% w/v (aqueous)
    Indications
    Thyrotoxicosis
  340. Iohexol General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
    X-ray contrast media, iodinated
  341. Ipratropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler
    Indications
    Chronic obstructive pulmonary disease Asthma
  342. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  343. Isoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  344. Isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg (scored)
    • Oral > Solid > tablet: 100 mg; 300 mg
    Indications
    Tuberculosis
  345. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
    Indications
    Tuberculosis
  346. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  347. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 75 mg
    • Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
    Indications
    Tuberculosis
  348. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  349. Isosorbide dinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
    Angina pectoris
  351. Ivacaftor General information
    Section
    Medicines for cystic fibrosis
    • Oral > Solid > tablet: 75 mg; 150 mg
    • Oral > Solid > granules: 59.5 mg; 75 mg
    Indications
    Cystic fibrosis
  352. Ivermectin General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 3 mg
    Indications
    Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
    Scabies
    Section
    Antifilarials
    • Oral > Solid > tablet: 3 mg
    Indications
    Lymphatic filariasis Onchocerciasis
  353. Kanamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  354. Ketamine General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)
    Indications
    Anaesthetics and therapeutic gases
  355. Lactulose General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid
    Indications
    Palliative care
  356. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  358. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  359. Lamotrigine General information
    Section
    Antiseizure medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
    Indications
    Epilepsy or seizures
  360. Latanoprost General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
    Indications
    Primary open-angle glaucoma
  361. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  362. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  363. Letrozole General information
    Section
    Ovulation inducers
    • Oral > Solid > dosage form: 2.5 mg
    Indications
    Female infertility without specification whether primary or secondary
  364. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  365. Levamisole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
    Indications
    Ascariasis
  366. Levetiracetam General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
    • Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
    Indications
    Epilepsy or seizures Status epilepticus
  367. Levodopa + benserazide General information
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to levodopa + carbidopa for Parkinson disease
  368. Levodopa + carbidopa General information
    Section
    Medicines for parkinsonism
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
    Indications
    Parkinson disease
  369. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  370. Levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Indications
    Contact with health services for insertion of contraceptive device
  371. Levonorgestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
    Indications
    Contact with health services for insertion of contraceptive device
  372. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  373. Lidocaine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Indications
    Ventricular tachyarrhythmia
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
    Local anaesthetics
  374. Lidocaine + epinephrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
    Local anaesthetics
  375. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg (scored)
    • Oral > Solid > tablet: 600 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  376. Liraglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  377. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  378. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  379. Lithium carbonate General information
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 300 mg
    Indications
    Bipolar or related disorders
  380. Loperamide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid > dosage form: 2 mg
    Indications
    Palliative care
  381. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
    • Oral > Solid > dosage form: 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  382. Loratadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  383. Lorazepam General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to diazepam for Anxiety
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Indications
    Status epilepticus
  384. Losartan General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Heart failure
  385. Lovastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  386. Magnesium sulfate General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
    Indications
    Severe pre-eclampsia Eclampsia
  387. Malaria vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain specified single infectious diseases
  388. Mannitol General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
    Indications
    Ocular hypertension Cerebral oedema
  389. Measles vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  390. Mebendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Indications
    Other specified echinococcosis
  391. Medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Indications
    Contact with health services for reasons associated with reproduction
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  392. Mefloquine General information
    Section
    Antimalarial medicines > Medicines for chemoprophylaxis in travellers
    • Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  393. Meglumine antimoniate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
    Indications
    Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis
  394. Meglumine iotroxate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
    X-ray contrast media, iodinated
  395. Melarsoprol General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
    Indications
    Rhodesiense trypanosomiasis Gambiense trypanosomiasis
  396. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  397. Meningococcal meningitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  398. Mercaptopurine General information
    Section
    Cytotoxic medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 50 mg tablet
    Indications
    Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities
  399. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
    Section
    Medicines for bacterial central nervous system infections
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  400. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  401. Mesalazine General information
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis
  402. Mesna General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
    • Oral > Solid > tablet: 400 mg; 600 mg
    • Oral > Other: 600 mg
    • Oral > Solid > tablet: 400 mg
    Indications
    Other specified malignant neoplasms of the ovary Osteosarcoma of bone and articular cartilage of other specified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Germ cell tumour of testis
  403. Metformin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  404. Methadone General information
    Section
    Medicines for opioid use disorders
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Indications
    Opioid dependence
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
    Indications
    Chronic cancer pain
  405. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 5 mg; 10 mg
    Indications
    Thyrotoxicosis
  406. Methotrexate General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
    • Oral > Solid: 2.5 mg (as sodium salt)
    Indications
    Malignant trophoblastic neoplasms of placenta Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
    Indications
    Psoriasis of unspecified type
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Indications
    Juvenile idiopathic arthritis
  407. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  408. Methyldopa General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
    Indications
    Gestational hypertension
  409. Methylergometrine General information
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine for Postpartum haemorrhage
  410. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
    • Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified
  411. Methylthioninium chloride General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
    Indications
    Acquired methaemoglobinaemia
  412. Metoclopramide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (scored) (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Nausea or vomiting
  413. Metoprolol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
  414. Metronidazole General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Amoebiasis
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    First choice
    Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with ceftriaxone Necrotising fasciitis co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate)
    Second choice
    co-prescribed with ciprofloxacin Peritonitis (mild-moderate) co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate)
  415. Micafungin General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
    Indications
    Systemic or invasive candidosis
  416. Miconazole General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
    Indications
    Fungal infection of the skin
  417. Midazolam General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    Indications
    Status epilepticus Therapeutic equivalent to lorazepam for Status epilepticus
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL in 5 vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid > dosage form: 15 mg; 7.5 mg
    Indications
    Sedative-hypnotic and anxiolytic drugs
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
    • Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    • Oral > Solid > dosage form: 7.5 mg; 15 mg
    Indications
    Palliative care
  418. Mifepristone - misoprostol General information
    Section
    Medicines for medical abortion
    • Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
    Unspecified time of fetal death, cause not specified Induced abortion
  419. Miltefosine General information
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  420. Misoprostol General information
    Section
    Uterotonics
    • Local > Vaginal > tablet: 25 µg
    • Oral > Solid: 200 µg
    Indications
    Unspecified obstetric condition Postpartum haemorrhage
    Section
    Medicines for medical abortion
    • Oral > Solid > tablet: 200 µg
    Indications
    Spontaneous abortion, incomplete, without complication
  421. Mometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  422. Mometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  423. Morphine General information
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Opioids or related analgesics and agents affecting opioid receptors
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate); 5 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    • Oral > Solid > tablet: 10 mg immediate release (morphine sulfate)
    • Oral > Solid > dosage form: 5 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 30 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate)
    • Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)
    Indications
    Pain
  424. Moxidectin General information
    Section
    Antifilarials
    • Oral > Solid > tablet: 2 mg
    Indications
    Therapeutic equivalent to ivermectin for Lymphatic filariasis Therapeutic equivalent to ivermectin for Onchocerciasis
  425. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 400 mg
    • Oral > Solid > dispersible tablet: 100 mg
    Indications
    Tuberculosis Multi-drug resistant Mycobacterium tuberculosis
  426. Mpox vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  427. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Sachets containing:
    • - iron (elemental) 12.5 mg (as coated ferrous fumarate)
    • - zinc (elemental) 5 mg
    • - vitamin A 300 micrograms
    • - with or without other micronutrients at recommended daily values
    Indications
    Iron deficiency anaemia
  428. Multiple micronutrient supplement General information
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
    Indications
    Maternal care for other specified conditions predominantly related to pregnancy
  429. Mumps vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  430. Mupirocin General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
    Indications
    Superficial bacterial folliculitis Impetigo
  431. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  432. Naloxone General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
    Indications
    Unintentional exposure to or harmful effects of opioids or related analgesics
  433. Naltrexone General information
    Section
    Medicines for alcohol use disorders
    • Parenteral > General injections > IM: 380 mg in vial (extended-release)
    • Oral > Solid > tablet: 50 mg
    Indications
    Disorders due to use of alcohol
  434. Naproxen General information
    Section
    Medicines for acute migraine attacks
    Indications
    Therapeutic equivalent to ibuprofen for Migraine
  435. Natamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
    Indications
    Infectious keratitis
  436. Neostigmine General information
    Section
    Medicines for myasthenia gravis
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    • Oral > Solid > tablet: 15 mg (neostigmine bromide)
    Indications
    Myasthenia gravis
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    • Oral > Solid > tablet: 15 mg (neostigmine bromide)
    Indications
    Myasthenia gravis Anticholinesterase reversible
  437. Netilmicin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  438. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > dispersible tablet: 50 mg
    • Oral > Solid > tablet: 200 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  439. Niclosamide General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
    Indications
    Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium
  440. Nicotinamide General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Pellagra
  441. Nicotine replacement therapy General information
    Section
    Medicines for nicotine use disorders
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
    • Oral > Solid > lozenge: 2 mg; 4 mg lozenge
    • Local > Buccal > Oral spray: 1 mg per actuation
    • Local > Buccal > Chewing gum: 2 mg; 4 mg
    Indications
    Nicotine dependence
  442. Nifedipine General information
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Indications
    Preterm labour without delivery
  443. Nifurtimox General information
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Chagas disease
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
    Gambiense trypanosomiasis
  444. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  445. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  446. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    First choice
    Infectious cystitis
  447. Nitrous oxide General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  448. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Melanoma of skin Melanoma of skin
  449. Norethisterone General information
    Section
    Progestogens
    Indications
    Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle
  450. Norethisterone enantate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
    Indications
    Contact with health services for reasons associated with reproduction
  451. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome
    Section
    Medicines for Guillain-Barré syndrome
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    Indications
    Acute inflammatory demyelinating polyneuropathy
  452. Nystatin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL
    • Local > Topical > Other: 100000 IU pessary
    • Oral > Solid > dosage form: 500000 IU
    • Oral > Solid > lozenge: 100000 IU
    Indications
    Candidosis
  453. Octreotide General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  454. Ofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    Indications
    Therapeutic equivalent to ciprofloxacin for Infectious diseases of external ear
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Other specified conjunctivitis Infectious keratitis
  455. Olanzapine General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 10 mg in vial powder for injection
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  456. Omeprazole General information
    Section
    Antiulcer medicines
    • Parenteral > General injections > IV: 40 mg in vial
    • Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid
    • Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg
    Indications
    Gastrointestinal bleeding Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  457. Ondansetron General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)
    • Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
    • Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule
    • Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
    • Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)
    Indications
    Nausea or vomiting
  458. Oral rehydration salts General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq or mmol/L
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mEq or mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq or mmol/L
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mEq or mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Diarrhoea
  459. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet 20 mg (co-packaged)
    Indications
    Diarrhoea
  460. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  461. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  462. Oxamniquine General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid > capsule: 250 mg
    Indications
    Schistosomiasis due to Schistosoma mansoni
  463. Oxycodone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  464. Oxygen General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Indications
    Anaesthetics and therapeutic gases
    Section
    Medical gases
    • Respiratory > Inhalation:
    Indications
    Respiratory failure as acute or chronic
  465. Oxytetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma
  466. Oxytocin General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
    Indications
    Postpartum haemorrhage
  467. P-aminosalicylate sodium General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  469. Paliperidone General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders
  470. Palonosetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  471. Pancreatic enzymes General information
    Section
    Gastrointestinal medicines
    • Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.
    • *Units expressed in Ph. Eur
    Indications
    Enzyme intestinal
    Section
    Medicines for cystic fibrosis
    • Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.
    • *Units expressed in Ph. Eur
    Indications
    Cystic fibrosis
  472. Paracetamol (acetaminophen) General information
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 100 mg; 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Pain
    Section
    Medicines for acute migraine attacks
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Migraine
  473. Paromomycin General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Indications
    Visceral leishmaniasis
  474. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  475. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  476. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    Indications
    Melanoma of skin Malignant neoplasms of cervix uteri Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to nivolumab for Melanoma of skin
  477. Penicillamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  478. Pentamidine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)
    Indications
    Pneumocystosis
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
    Indications
    Gambiense trypanosomiasis
  479. Perindopril + amlodipine + indapamide General information
    Section
    Antihypertensive medicines
    • Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg
    Indications
    Essential hypertension
  480. Permethrin General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
    Indications
    Pediculosis corporis Pediculosis capitis Scabies
  481. Pertussis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  482. Phenobarbital General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg
    Indications
    Status epilepticus Epilepsy or seizures
  483. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    First choice
    Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
  484. Phenytoin General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 30 mg per 5 mL (phenytoin)
    • Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
    • Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
    • Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)
    Indications
    Epilepsy or seizures
  485. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution
    • Oral > Solid > tablet: 5 mg tablet
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn
  486. Pilocarpine General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
    Indications
    Acute angle closure with pupillary block Ocular hypertension Primary open-angle glaucoma
  487. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescribed with clindamycin Necrotising fasciitis
  488. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  489. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  490. Pneumococcal vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  491. Podophyllotoxin General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin for Anogenital warts Therapeutic equivalent to podophyllum resin for Plantar warts
  492. Podophyllum resin General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
    Indications
    Anogenital warts Plantar warts
  493. Poliomyelitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  494. Polygeline General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    Indications
    Therapeutic equivalent to dextran 70 for Hypovolaemia
  495. Polymyxin B (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  496. Porcatant alfa General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  497. Potassium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Hypokalaemia
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Hypokalaemia
  498. Potassium ferric hexacyanoferrate (Prussian blue) General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  499. Potassium iodide General information
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Sporotrichosis
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 65 mg (scored)
    Indications
    Thyrotoxicosis
  500. Potassium permanganate General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
    Indications
    Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin and subcutaneous tissue Impetigo
  501. Povidone iodine General information
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
    Povidone iodine
  502. Pravastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  503. Praziquantel General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Hymenolepiasis Diphyllobothriasis
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Indications
    Cysticercosis of central nervous system
  504. Precipitated sulfur General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Ointment:
    Indications
    Therapeutic equivalent to benzyl benzoate for Pthiriasis Therapeutic equivalent to benzyl benzoate for Pediculosis corporis Therapeutic equivalent to benzyl benzoate for Pediculosis capitis Therapeutic equivalent to benzyl benzoate for Scabies
  505. Prednisolone General information
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
    Indications
    Therapeutic equivalent to hydrocortisone for Crohn disease site Crohn disease site Ulcerative colitis
    Section
    Hormones and antihormones
    • Oral > Solid: 5 mg; 25 mg
    • Oral > Liquid: 5 mg per mL
    Indications
    Plasma cell myeloma Follicular lymphoma Malignant neoplasms of prostate Hodgkin lymphoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Indications
    Scleritis Anterior uveitis
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Adrenocortical insufficiency
    Section
    Medicines for cluster headache
    • Oral > Solid > tablet: 25 mg; 5 mg
    Indications
    Trigeminal autonomic cephalalgias
  506. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Antiallergics and medicines used in anaphylaxis
    Indications
    Therapeutic equivalent to prednisolone for Allergic or hypersensitivity conditions of unspecified type
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Therapeutic equivalent to prednisolone for Adrenocortical insufficiency
  507. Pretomanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  508. Primaquine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  509. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    First choice
    Congenital syphilis [children]
    Second choice
    Syphilis
  510. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  511. Progesterone vaginal ring General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
    Indications
    Contact with health services for contraceptive management
  512. Propanol General information
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to ethanol for Denatured alcohol
  513. Propofol General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
    Indications
    Anaesthetics and therapeutic gases
  514. Propranolol General information
    Section
    Medicines for migraine prophylaxis
    • Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)
    Indications
    Migraine
  515. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  516. Protamine sulfate General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors
  517. Protionamide General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis
  518. Pyrantel General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
    Indications
    Ascariasis Trichuriasis Enterobiasis Hookworm diseases
  519. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 400 mg; 500 mg
    Indications
    Tuberculosis
  520. Pyridostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
    • Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
    Indications
    Myasthenia gravis
    Section
    Medicines for myasthenia gravis
    • Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
    • Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
    Indications
    Myasthenia gravis
  521. Pyridoxine General information
    Section
    Vitamins and minerals
    • Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)
    Indications
    Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia
  522. Pyrimethamine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
    Toxoplasmosis
  523. Quetiapine General information
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
    Indications
    Bipolar or related disorders
  524. Quinine General information
    Section
    Antimalarial medicines > Medicines for curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion
    Indications
    Malaria due to Plasmodium falciparum
  525. Rabies vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  526. Raltegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  527. Ranitidine General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
    Indications
    Gastro-oesophageal reflux disease Peptic ulcer, site unspecified
  528. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution
    Indications
    Tumour lysis syndrome
  529. Ravidasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  530. Ready to use therapeutic food General information
    Section
    Therapeutic foods
    • Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
    Indications
    Acute malnutrition in infants, children or adolescents
  531. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  532. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  533. Resin-based composite (high-viscosity) General information
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use capsule or multi-use syringe
    Indications
    Dental caries
  534. Resin-based composite (low-viscosity) General information
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use applicator or multi-use bottle
    Indications
    Dental caries
  535. Respiratory syncytial virus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  536. Retinol General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate)
    • Oral > Liquid: 100000 IU per mL (as palmitate or acetate)
    • Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule
    Indications
    Vitamin A deficiency
  537. Ribavirin General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  538. Riboflavin General information
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
    Indications
    Vitamin B2 deficiency
  539. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  540. Rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  541. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Tuberculosis Latent tuberculosis
  542. Risperidone General information
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
    • Parenteral > General injections > IM:
    Indications
    Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone for Schizophrenia or other primary psychotic disorders
  543. Ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  544. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  545. Rivaroxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  546. Rotavirus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  547. Rubella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  548. Salbutamol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers
    Indications
    Chronic obstructive pulmonary disease Asthma
  549. Salicylic acid General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses
  550. Selenium sulfide General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
    Indications
    Seborrhoeic dermatitis Pityriasis versicolor
  551. Semaglutide General information
    Section
    Hypoglycaemic agents
    • Parenteral > General injections > SC: 0.68 mg per mL in prefilled pen; 1.34 mg per mL in prefilled pen; 2.68 mg per mL in prefilled pen
    Indications
    Type 2 diabetes mellitus
  552. Senna General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Palliative care
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
    Constipation
  553. Sevoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
    Indications
    Anaesthetics and therapeutic gases
  554. Silver diamine fluoride General information
    Section
    Dental medicines and preparations
    • Local > Dental > Solution: 38% w/v
    Indications
    Dental caries
  555. Silver sulfadiazine General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
    Burns
  556. Simvastatin General information
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
    Indications
    Mixed hyperlipidaemia Coronary atherosclerosis
  557. Sodium calcium edetate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  558. Sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  559. Sodium hydrogen carbonate General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
    Acidosis
  560. Sodium nitrite General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  561. Sodium nitroprusside General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
    Indications
    Hypertensive crisis
  562. Sodium stibogluconate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  563. Sodium thiosulfate General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 15%
    Indications
    Pityriasis versicolor
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  564. Sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg; 400 mg
    • Oral > Solid > granules: 200 mg in sachet
    Indications
    Chronic hepatitis C
  565. Sofosbuvir + velpatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
    • Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet
    Indications
    Chronic hepatitis C
  566. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Gonococcal infection
  567. Spironolactone General information
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Liquid: 25 mg per 5 mL
    • Oral > Solid > tablet: 25 mg; 12.5 mg
    Indications
    Oedema Ascites
  568. Streptokinase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
    Indications
    Acute myocardial infarction
  569. Streptomycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  570. Succimer General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  571. Sulfadiazine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
    Toxoplasmosis
  572. Sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > Medicines for chemoprevention
    • Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet
    Indications
    Malaria
  573. Sulfamethoxazole + trimethoprim General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Pneumocystosis
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    First choice
    Infectious cystitis
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent
  574. Sulfasalazine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Indications
    Rheumatoid arthritis, serology unspecified
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema: 3 g per 100 mL
    Indications
    Crohn disease site Ulcerative colitis
  575. Sumatriptan General information
    Section
    Medicines for acute migraine attacks
    • Oral > Solid > tablet: 50 mg
    Indications
    Migraine
    Section
    Medicines for cluster headache
    • Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe
    Indications
    Trigeminal autonomic cephalalgias
  576. Sunscreen, broad-spectrum General information
    Section
    Dermatological medicines > Sunscreens
    • Topical:
    • Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).
    Indications
    Albinism or other specified genetically-determined hypomelanotic disorders
  577. Suramin sodium General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    Rhodesiense trypanosomiasis
  578. Suxamethonium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)
    Indications
    Muscle relaxants
  579. Tacalcitol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type
  580. Tacrolimus General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  581. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  582. Tedizolid General information
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus
  583. Telmisartan + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  584. Telmisartan + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  585. Tenofovir disoproxil fumarate General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  586. Terbinafine General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
    Indications
    Fungal infection of the skin
  587. Terbutaline General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to salbutamol for Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol for Asthma
  588. Terizidone General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis
  589. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  590. Tetanus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  591. Tetracaine General information
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  592. Tetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
    Indications
    Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
  593. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  594. Thiamine General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)
    • Oral > Solid > tablet: 50 mg (hydrochloride)
    Indications
    Vitamin B1 deficiency
  595. Thiopental General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    Indications
    Therapeutic equivalent to propofol for Anaesthetics and therapeutic gases
  596. Tick-borne encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  597. Timolol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
    Indications
    Primary open-angle glaucoma Ocular hypertension
  598. Tinidazole General information
    Section
    Antiamoebic and antigiardiasis medicines
    Indications
    Therapeutic equivalent to metronidazole for Amoebiasis
  599. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  600. Tiotropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > powder: 18 µg in capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler
    Indications
    Chronic obstructive pulmonary disease
  601. Tirzepatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  602. Tobramycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  603. Torasemide General information
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
  604. Tranexamic acid General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
  605. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  606. Triamcinolone hexacetonide General information
    Section
    Medicines for juvenile joint diseases
    • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial
    Indications
    Juvenile idiopathic arthritis
  607. Triclabendazole General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 250 mg (scored)
    Indications
    Paragonimiasis Fascioliasis
  608. Trihexyphenidyl General information
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to biperiden for Parkinson disease
  609. Trimethoprim General information
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    First choice
    Infectious cystitis
  610. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  611. Tropicamide General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
    Cycloplegic drug
  612. Tropisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  613. Tuberculin, purified protein derivative General information
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
    Indications
    Mycobacterial diseases
  614. Typhoid vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  615. Ulipristal General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
    Indications
    Contact with health services for postcoital contraception
  616. Umeclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease
  617. Urea General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
    Indications
    Xerosis cutis or asteatosis
    Section
    Dermatological medicines > Moisturizers
    • Local > Topical > Cream: 5 per %
    Indications
    Atopic eczema
  618. Ustekinumab General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen
    Indications
    Psoriasis of unspecified type
  619. Valaciclovir General information
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella Therapeutic equivalent to aciclovir for Herpes simplex infections
    Section
    Medicines for viral central nervous system infections
    Indications
    Therapeutic equivalent to aciclovir for Herpes simplex infections Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella
  620. Valganciclovir General information
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
    • Oral > Solid > tablet: 450 mg (as hydrochloride)
    Indications
    Cytomegaloviral retinitis
  621. Valproic acid (sodium valproate) General information
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
    Indications
    Bipolar or related disorders
    Section
    Antiseizure medicines
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule
    Indications
    Epilepsy or seizures Status epilepticus
  622. Valsartan + amlodipine + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg
    Indications
    Essential hypertension
  623. Vancomycin General information
    Section
    Watch group antibiotics
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    First choice
    Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis
    Second choice
    Neutropenia (high-risk) Intestinal infections due to Clostridioides difficile
  624. Varenicline General information
    Section
    Medicines for nicotine use disorders
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Nicotine dependence
  625. Varicella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  626. Vecuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
    Muscle relaxants
  627. Verapamil General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Supraventricular tachyarrhythmia
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Angina pectoris
    Section
    Medicines for cluster headache
    • Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)
    Indications
    Trigeminal autonomic cephalalgias
  630. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site
  631. Voriconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
    Indications
    Chronic pulmonary aspergillosis Invasive aspergillosis
  632. Warfarin General information
    Section
    Medicines affecting coagulation
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    Indications
    Other specified diseases of arteries or arterioles Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation
  633. Water for injection General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
    Indications
    Unspecified appropriateness of dosing or administration without injury or harm
  634. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  635. Xylometazoline General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL
    • Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL
    Indications
    Nasal congestion
  636. Yellow fever vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  637. Zanubrutinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 80 mg
    Indications
    Therapeutic equivalent to ibrutinib for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  638. Zidovudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid > tablet: 300 mg
    • Oral > Solid > capsule: 250 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  639. Zinc sulfate General information
    Section
    Medicines for diarrhoea
    • Oral > Solid > dispersible tablet: 20 mg (scored)
    Indications
    Diarrhoea
  640. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow
  641. Zuclopenthixol decanoate General information
    Section
    Medicines for psychotic disorders
    Indications
    Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders